and Daily SiHy lenses and Bausch + Lomb ULTRA ® in our contact lens business. Surgical segment revenue was $231 million for the fourth quarter of 2024, as compared to $204 million for the fourth ...

After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb (BLCO) chairman and CEO Brent Saunders won't be making in 2025. The one for his contact ...

Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake.

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

"Underpinning our recent success is a commitment to long-term, profitable growth," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Our refocused pipeline is now filled with promise and ...

Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you find your favorite podcasts. After completing $300 billion in healthcare deals over several decades, there is ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 ...

Detailed price information for Bausch & Lomb Corp (BLCO-N) from The Globe and Mail including charting and trades.